Valneva (NASDAQ:VALN) and IM Cannabis (NASDAQ:IMCC) Head to Head Contrast

Valneva (NASDAQ:VALN) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Valneva and IM Cannabis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
IM Cannabis	-27.65%	-585.96%	-39.96%

Risk & Volatility

Valneva has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.

Insider & Institutional Ownership

11.4% of Valneva shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Valneva and IM Cannabis”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56 million	2.37	-$130.33 million	($1.87)	-2.64
IM Cannabis	$39.17 million	0.02	-$8.10 million	($1.75)	-0.08

IM Cannabis has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Valneva and IM Cannabis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2	0	3	0	2.20
IM Cannabis	1	0	0	0	1.00

Valneva presently has a consensus price target of $11.97, indicating a potential upside of 142.90%. Given Valneva’s stronger consensus rating and higher probable upside, analysts clearly believe Valneva is more favorable than IM Cannabis.

Summary

Valneva beats IM Cannabis on 9 of the 14 factors compared between the two stocks.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

About IM Cannabis

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.